StreetInsider.com News Articles

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Wed, 21 Oct 2026 18:10:00 -0400

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.
FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Wed, 21 Oct 2026 18:10:00 -0400

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.
FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients

US Seeks More Competition In Kidney Treatment Market - Axios

Tue, 20 Oct 2026 12:04:56 -0400

(Updated - October 20, 2026 12:04 PM EDT)

US Seeks More Competition In Kidney Treatment Market - Axios

DaVita (NYSE: DVA) falls 5%, Fresenius Medical Care (NYSE: FMS) -2.25%

US Seeks More Competition In Kidney Treatment Market - Axios

Tue, 20 Oct 2026 12:04:56 -0400

(Updated - October 20, 2026 12:04 PM EDT)

US Seeks More Competition In Kidney Treatment Market - Axios

DaVita (NYSE: DVA) falls 5%, Fresenius Medical Care (NYSE: FMS) -2.25%

US Seeks More Competition In Kidney Treatment Market - Axios

Tue, 20 Oct 2026 12:04:56 -0400

(Updated - October 20, 2026 12:04 PM EDT)

US Seeks More Competition In Kidney Treatment Market - Axios

DaVita (NYSE: DVA) falls 5%, Fresenius Medical Care (NYSE: FMS) -2.25%

US Seeks More Competition In Kidney Treatment Market - Axios

Tue, 20 Oct 2026 12:04:56 -0400

(Updated - October 20, 2026 12:04 PM EDT)

US Seeks More Competition In Kidney Treatment Market - Axios

DaVita (NYSE: DVA) falls 5%, Fresenius Medical Care (NYSE: FMS) -2.25%

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Mon, 19 Oct 2026 09:00:00 -0400

New U.S. real-world evidence demonstrates high-volume hemodiafiltration (HvHDF) can be successfully delivered in routine clinical practice, with treatment targets comparable to those reported in Europe
GLP-1 receptor agonist use associated with significantly lower mortality and fewer hospitalizations among dialysis patients

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

Mon, 19 Oct 2026 09:00:00 -0400

New U.S. real-world evidence demonstrates high-volume hemodiafiltration (HvHDF) can be successfully delivered in routine clinical practice, with treatment targets comparable to those reported in Europe
GLP-1 receptor agonist use associated with significantly lower mortality and fewer hospitalizations among dialysis patients

Fresenius Medical Care AG & Co. KGaA (FME:GR) (FMS) PT Raised to EUR32 at Morgan Stanley

Fri, 16 Oct 2026 05:50:34 -0400

Morgan Stanley analyst Robert Davies raised the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR31.00) while maintaining a Underweight rating.

Fresenius Medical Care AG & Co. KGaA (FME:GR) (FMS) PT Raised to EUR32 at Morgan Stanley

Fri, 16 Oct 2026 05:50:34 -0400

Morgan Stanley analyst Robert Davies raised the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR31.00) while maintaining a Underweight rating.

Fresenius Medical Care AG & Co. KGaA (FME:GR) (FMS) PT Raised to EUR32 at Morgan Stanley

Fri, 16 Oct 2026 05:50:34 -0400

Morgan Stanley analyst Robert Davies raised the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR31.00) while maintaining a Underweight rating.

Fresenius Medical Care AG & Co. KGaA (FME:GR) (FMS) PT Raised to EUR32 at Morgan Stanley

Fri, 16 Oct 2026 05:50:34 -0400

Morgan Stanley analyst Robert Davies raised the price target on Fresenius Medical Care AG & Co. KGaA (FME:GR) (NYSE: FMS) to EUR32.00 (from EUR31.00) while maintaining a Underweight rating.

Focus Graphite Advances Lac Knife Toward Construction Readiness with Up to C$1.93 Million in Combined Government Infrastructure Support

Thu, 15 Oct 2026 05:00:00 -0400

Project access road geotechnical investigations and detailed engineering advance as Focus progresses critical transportation infrastructure planning

Ottawa, Ontario--(Newsfile Corp. - October 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the engagement of Construction & Expertise PG ("PG") to advance geotechnical investigations and detailed engineering for the proposed all-season access road to its flagship Lac Knife Graphite Project ("Lac Knife" or the "Project") in Quebec.

The engagement marks an important step toward construction

Focus Graphite Advances Lac Knife Toward Construction Readiness with Up to C$1.93 Million in Combined Government Infrastructure Support

Thu, 15 Oct 2026 05:00:00 -0400

Project access road geotechnical investigations and detailed engineering advance as Focus progresses critical transportation infrastructure planning

The engagement marks an important step toward construction

Focus Graphite Advances Lac Knife Toward Construction Readiness with Up to C$1.93 Million in Combined Government Infrastructure Support

Thu, 15 Oct 2026 05:00:00 -0400

Project access road geotechnical investigations and detailed engineering advance as Focus progresses critical transportation infrastructure planning

The engagement marks an important step toward construction

Focus Graphite Advances Lac Knife Toward Construction Readiness with Up to C$1.93 Million in Combined Government Infrastructure Support

Thu, 15 Oct 2026 05:00:00 -0400

Project access road geotechnical investigations and detailed engineering advance as Focus progresses critical transportation infrastructure planning

The engagement marks an important step toward construction

Fresenius Medical Care (FMS) PT Lowered to $24 at Truist Securities

Mon, 12 Oct 2026 07:08:55 -0400

Truist Securities analyst David MacDonald lowered the price target on Fresenius Medical Care (NYSE: FMS) to $24.00 (from $25.00) while maintaining a Hold rating.

Form 6-K Fresenius Medical Care For: Oct 07

Wed, 07 Oct 2026 14:20:00 -0400

si-local-file:///var/storage/secattach/20261007/27160683.html

Fresenius Medical Care tumbles on CEO transition announcement

Wed, 07 Oct 2026 13:07:43 -0400

Investing.com -- Fresenius Medical Care Corporation ADRs (NYSE:FMS) dropped nearly 7% Wednesday after the company announced a leadership transition, with Shervin Korangy set to become CEO effective October 12, 2026.

The dialysis products and services provider said Korangy will succeed Helen Giza, who has served as CEO and Chair of the Management Board for four years. The appointment comes as the company completes its FME25+ transformation program, which reduced its cost base by approximately EUR 1.2 billion.

Korangy, 51, most recently served as CEO of U.S.-headquartered BVI Medical, where he transformed the business into a global leader in surgical eye care. He

Fresenius Medical Care names Shervin Korangy as new CEO

Wed, 07 Oct 2026 11:29:36 -0400

Fresenius Medical Care (NYSE: FMS) announced that Shervin J. Korangy, 51, will become Chief Executive Officer and Chair of the Management Board, effective October 12, 2026, succeeding Helen Giza, who served as CEO for four years after three years as CFO.

The Supervisory Board unanimously appointed Korangy, who had been a member of FME's Supervisory Board since 2023. He resigned from that position upon his appointment as CEO.

Korangy most recently served as President and CEO of BVI Medical, an ophthalmology-focused medical technology company, from 2017 to 2026. Before BVI Medical, he held senior executive roles at Novartis Group AG, spanning medical

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

Wed, 07 Oct 2026 11:28:00 -0400

BAD HOMBURG, Germany, Oct. 7, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced that Shervin J. Korangy (51) will become Chief Executive Officer (CEO) and Chair of the Management Board, effective October 12, 2026. The Supervisory Board unanimously appointed him to succeed Helen Giza (58), who has served as CEO and Chair of the Management Board for four years, following three

Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth

Wed, 07 Oct 2026 11:28:00 -0400

Fresenius Medical Care names Korangy as new management board chair

Wed, 07 Oct 2026 11:14:47 -0400

The Supervisory Board of Fresenius Medical Care AG has unanimously appointed Shervin J. Korangy as Chairman of the Management Board, effective October 12, 2026.

Korangy, who previously served as a member of the company's Supervisory Board, has resigned from that position ahead of his new role.

Current Chairwoman of the Management Board Helen Giza will leave the company at the end of October 11, 2026. The Supervisory Board acknowledged her service to the company.

Fresenius Medical Care names Korangy as new management board chair

Wed, 07 Oct 2026 11:14:47 -0400

The Supervisory Board of Fresenius Medical Care AG has unanimously appointed Shervin J. Korangy as Chairman of the Management Board, effective October 12, 2026.

Korangy, who previously served as a member of the company's Supervisory Board, has resigned from that position ahead of his new role.

Current Chairwoman of the Management Board Helen Giza will leave the company at the end of October 11, 2026. The Supervisory Board acknowledged her service to the company.

Fresenius Medical Care names Korangy as new management board chair

Wed, 07 Oct 2026 11:14:47 -0400

The Supervisory Board of Fresenius Medical Care AG has unanimously appointed Shervin J. Korangy as Chairman of the Management Board, effective October 12, 2026.

Korangy, who previously served as a member of the company's Supervisory Board, has resigned from that position ahead of his new role.

Current Chairwoman of the Management Board Helen Giza will leave the company at the end of October 11, 2026. The Supervisory Board acknowledged her service to the company.